Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Continued Access Protocol

NCT00889681 · View on ClinicalTrials.gov ↗

Study Summary

This Continued Access Protocol has been written to allow ongoing treatment of subjects at selected investigational sites while the marketing application for the Arctic Front® Cryoablation System is under review. This study will also allow collection of additional safety data following modifications implemented into the Arctic Front® Catheter and Cryoablation System.

Conditions Studied

Interventions

  • DEVICE Arctic Front Cardiac Cryoablation System

Study Locations (10)

California

  • Cedars Sinai Medical Center — Los Angeles
  • Stanford Hospital & Clinical — Stanford

Virginia

  • Inova Research Center — Falls Church
  • Virginia Commonwealth University Health System — Richmond

Arizona

  • Banner Good Samaritan — Phoenix

Florida

  • Bay Heart Group — Tampa

Georgia

  • Piedmont Hospital — Atlanta

Massachusetts

  • Massachusetts General Hospital — Boston

Minnesota

  • Mayo Clinic — Rochester

Texas

  • Baylor Heart & Vascular Hospital — Dallas

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2009-03
Est. Completion 2013-10
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00889681

The ClinicalTrials.gov registry entry for NCT00889681 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 56 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention — of which Arctic Front Cardiac Cryoablation System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00889681 reports 10 study locations spanning 8 distinct geographic areas — top geographies include California, Virginia, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00889681 about?

NCT00889681 is a clinical study titled "Continued Access Protocol". This Continued Access Protocol has been written to allow ongoing treatment of subjects at selected investigational sites while the marketing application for the Arctic Front® Cryoablation System is under review. This study will also allow collection of additional safety data following modifications ...

What is the current status of trial NCT00889681?

This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2009-03. Estimated completion is 2013-10.

What conditions does trial NCT00889681 study?

This clinical trial studies the following conditions: Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00889681?

The interventions under investigation include: Arctic Front Cardiac Cryoablation System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00889681?

This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 56 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00889681 being conducted?

This trial has 10 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial